Alzheimer's drug that can slow disease gets backing from FDA advisers | Top Stories

A closely watched Alzheimer’s drug from Eli Lilly won the backing of federal health advisers on Monday, setting the stage for the treatment’s expected approval for people with mild dementia

Related Keywords

Japan , Washington , United States , Japanese , Thomas Montine , Eli Lilly , Tanya Simuni , National Institutes Of Health , Northwestern University , Stanford University , Drug Administration , Dean Follmann , National Institutes ,